GlobeNewsWire
04 Jan 2026, 17:00 UTC · 37w ago
Verdict
Headline leans bearish. We score TLX −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA issued a Complete Response Letter (CRL) rejecting a Biologics License Application (BLA) for Telix's prostate cancer drug TLX591 due to manufacturing (CMC) and Form 483 deficiencies.
More negative than 99% of claims this week
Telix Pharmaceuticals received a subpoena from the SEC regarding its development disclosures.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 95% of claims this week
A securities class action lawsuit has been filed alleging that Telix materially misrepresented the progress of TLX591 and the reliability of its third-party manufacturing chain.
More negative than 86% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
Facing a securities class action lawsuit following an SEC subpoena, FDA manufacturing failures, and a 21% stock drop.
More negative than 86% of ticker scores this week
Mentioned as having a stock plunge due to allegedly misleading financial statements.
More negative than 86% of ticker scores this week
Mentioned as having a stock plunge due to allegedly misleading financial statements.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
2h ago
+46.1%
Price is moving against the score
$11.13 vs $7.62 close before publication (Jan 2) · not market-adjusted
TLX chart →
